 NEW HAVEN, Conn., Sept. 12, 2021 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. BioXcel or the Company Nasdaq: BTAI, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing Phase 1b2 trial of BXCL701, the Companys investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology ESMO Congress, which will take place virtually from September 16-21, 2021. 